A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease

(2018) Jingjing Tai et al.   BRAIN RESEARCH

Treatment with a GLP−1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

(2017) Rodrigo B. Mansur et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation

(2017) Stephen M. Day et al.   HIPPOCAMPUS

Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

(2017) Rodrigo B. Mansur et al.   JOURNAL OF AFFECTIVE DISORDERS

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

(2016) Henrik H. Hansen et al.   BRAIN RESEARCH

Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells

(2016) Jaishree Jalewa et al.   JOURNAL OF NEUROCHEMISTRY

[Gly14]-Humanin Protects Against Amyloid β Peptide-Induced Impairment of Spatial Learning and Memory in Rats

(2016) Li Yuan et al.   Neuroscience Bulletin

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Michael Gejl et al.   Frontiers in Aging Neuroscience

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD)

(2015) Akira Nakajima et al.   BEHAVIOURAL BRAIN RESEARCH

Alcohol exposure after mild focal traumatic brain injury impairs neurological recovery and exacerbates localized neuroinflammation

(2015) Sophie X. Teng et al.   BRAIN BEHAVIOR AND IMMUNITY

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases

(2015) Valeria Calsolaro et al.   CNS DRUGS

Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease

(2015) Domenico Nuzzo et al.   Current Alzheimer Research

Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models

(2015) Erika Calvo-Ochoa et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice

(2015) Jason K. Clark et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Diabetes and Alzheimer Disease, Two Overlapping Pathologies with the Same Background: Oxidative Stress

(2015) Sergio Rosales-Corral et al.   Oxidative Medicine and Cellular Longevity

Insulin resistance in brain alters dopamine turnover and causes behavioral disorders

(2015) Andre Kleinridders et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer’s Disease: Impacts on Cognitive Decline

(2015) Jennifer Walker et al.   Nutrients

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

(2015) Simon C. Cork et al.   Molecular Metabolism

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

(2014) Christian Hölscher   BIOCHEMICAL SOCIETY TRANSACTIONS

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

(2014) D. Allan Butterfield et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

(2014) Paula L. McClean et al.   NEUROPHARMACOLOGY

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats

(2014) H.-Y. Cai et al.   NEUROSCIENCE

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship

(2013) N. T. Vagelatos et al.   EPIDEMIOLOGIC REVIEWS

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model

(2013) Emilie Faivre et al.   Alzheimers Research & Therapy

Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD)

(2012) Mohammed Filali et al.   BEHAVIOURAL BRAIN RESEARCH

The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain

(2012) Vadivel Parthsarathy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

(2012) Konrad Talbot et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice

(2012) T. Ma et al.   JOURNAL OF NEUROSCIENCE

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

(2012) Wei-Na Han et al.   NEUROBIOLOGY OF AGING

The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease

(2012) Caitriona M. Long-Smith et al.   NEUROMOLECULAR MEDICINE

The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease

(2012) A.M. Duffy et al.   NEUROSCIENCE

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis

(2011) Emilie Faivre et al.   JOURNAL OF NEUROPHYSIOLOGY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes

(2011) Ying Liu et al.   JOURNAL OF PATHOLOGY

Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions

(2011) Helgi B. Schiöth et al.   MOLECULAR NEUROBIOLOGY

Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β

(2011) Jihoon Jo et al.   NATURE NEUROSCIENCE

Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

(2010) Kawser Akter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transient Early-Life Forebrain Corticotropin-Releasing Hormone Elevation Causes Long-Lasting Anxiogenic and Despair-Like Changes in Mice

(2010) B. J. Kolber et al.   JOURNAL OF NEUROSCIENCE

Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model

(2010) Xu Wang et al.   Molecular Neurodegeneration

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

(2010) X.H. Wang et al.   NEUROSCIENCE

Light and Electron Microscopy Study of Glycogen Synthase Kinase-3β in the Mouse Brain

(2010) Emma Perez-Costas et al.   PLoS One

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

(2009) Fernanda G. De Felice et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA